Connect Biopharma Advances Rademikibart Toward Phase 3 In COPD
(RTTNews) - Wednesday, Connect Biopharma Holdings (CNTB) reported positive topline results from a global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation.